Expected weight loss: 13 kg (mostly appetite-driven reduction) 1.0 mg Weeks 912 Maximum Ozempic dose and the midpoint of Wegovy titration
Novanex protocols enhance safety for injectables by emphasizing gradual dose escalation and continuous physician oversight
Instructions for eating Important: If you take a GLP-1 medicine, do not follow these instructions
Easy to Monitor : The thigh is relatively easy to monitor, and many people find it easy to control the injection angle, making it more manageable
glucagon suppression, lowering hepatic glucose output Central Nervous System: Decreases food intake by targeting homeostatic and hedonic appetite pathways (hindbrain/hypothalamus), reducing hunger and cravings, and enhancing satiety Gastrointestinal Tract: Delays gastric emptying, contributing to satiety (transient effect at higher doses) Adiposity/Energy Intake : Weight loss is primarily driven by sustained reduction in caloric intake, not increased energy expenditure Biological Activity Potent GLP-1 receptor agonist Enhances insulin secretion (glucose-dependent) Suppresses glucagon secretion Reduces appetite and caloric intake Produces significant, sustained body weight loss Improves cardiometabolic risk factors (glycemia, blood pressure, lipids) Storage Refrigerate once reconstituted
At 0.25 mg, you are on the lowest possible dose
